Development and validation of a novel risk assessment model for necrotizing fasciitis in patients with diabetic foot

i

This article has been updated. A Correction to this article was published on .

i

The Original Article was published on

i

The Original Article was published on

i

This article has been updated

i

This article was retracted on

i

This article has been updated

Abstract

Aim: Necrotizing fasciitis (NF) is a severe and early challenging-to-identify complication of diabetic foot (DF). This study aimed to develop and validate a novel risk assessment model for NF with DF patients utilizing conventional clinical indicators. Methods: A retrospective analysis was conducted on 815 DF patients admitted to the First Affiliated Hospital of Chongqing Medical University between October 2018 and April 2022. Based on the presence of NF, patients were stratified into a DF group ( n = 703) and a DF complicated with NF (DNF) group ( n = 112). Clinically and statistically significant variables were converted into categorical form. A new risk assessment for DNF (NRADNF) nomogram was developed via multivariable stepwise logistic regression. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC) for discriminative ability, the Hosmer-Lemeshow goodness-of-fit test for calibration, decision curve analysis (DCA) for clinical utility, and bootstrap resampling for stability. Results: The final NRADNF model incorporated six indicators: age < 60 years, body temperature ≥ 38°C, foot skin necrosis, neutrophil-to-lymphocyte ratio (NLR) ≥ 8.5, hypersensitive C-reactive protein > 20 mg/L, and hemoglobin ≤ 100 g/L. The model demonstrated favorable predictive performance with an AUC of 0.815 (95% CI: 0.773, 0.857), and it was significantly superior to the RADNF model by our team ( P = 0.027). Calibration curves and the Hosmer-Lemeshow test indicated good accuracy. DCA confirmed the model’s clinical net benefit, and internal validation via bootstrap resampling supported its stability. Conclusions: Based on its favorable predictive performance and accessible indicators, the NRADNF model is suitable for preliminary screening of DNF in clinical practice.

Keywords

diabetic foot / necrotizing fasciitis / risk assessment / screening

CHANGE HISTORY

A Correction to this paper has been published:
https://doi.org

The Retraction Note was updated to reflect reception of statements of disagreement from all authors.

This article has been retracted.Please see the Retraction Notice for more detail:
https://doi.org

References

[1] Chen J, Xia J, Wang S, Wei Y. Research status of necrotizing fasciitis. Int J Orthop. 2011; 32: 96-8. China.

[2] Misiakos EP, Bagias G, Patapis P, Sotiropoulos D, Kanavidis P, Machairas A. Current concepts in the management of necrotizing fasciitis. Front Surg. 2014; 1: 36.

[3] Zhou L, Li H, Luo G ; CANF experts group representing the Chinese Burn Association; Editorial Board of the Chinese Journal of Burns and Wounds; Burn Medicine Branch of China International Exchange and Promotion Association for Medical and Healthcare. Consensus on the Diagnosis and Treatment of Adult Necrotizing Fasciitis (2025 Edition). Burns Trauma. 2025; 13:tkaf031.

[4] Yang S, Han R, Hu L. The pathophysiology and treatment in necrotizing fasciitis of diabetic foot. Chin J Inj Repair (Electron Ed). 2020; 15: 392-6. China.

[5] Baumann BM, Patterson RA, Farner MC. Necrotizing fasciitis in a woman with a diabetic foot infection and peripheral neuropathy. Postgrad Med. 2010; 122: 213-7.

[6] Grigoropoulou P, Eleftheriadou I, Jude EB, Tentolouris N. Diabetic Foot Infections: an Update in Diagnosis and Management. Curr Diab Rep. 2017; 17: 3.

[7] Wong CH, Khin LW, Heng KS, Tan KC, Low CO. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med. 2004; 32: 1535-41.

[8] Shimizu T, Tokuda Y. Necrotizing fasciitis. Intern Med. 2010; 49: 1051-7.

[9] Al-Hindawi A, McGhee J, Lockey J, Vizcaychipi M. Validation of the laboratory risk indicator for necrotising fasciitis scoring system (LRINEC) in a Northern European population. J Plast Reconstr Aesthet Surg. 2017; 70: 141-3.

[10] Tan JH, Koh BT, Hong CC, Lim SH, Liang S, Chan GW, et al. A comparison of necrotising fasciitis in diabetics and non-diabetics: a review of 127 patients. Bone Joint J. 2016; 98-B: 1563-8.

[11] Wu H, Liu S, Li C, Song Z. Modified Laboratory Risk Indicator for Necrotizing Fasciitis (m-LRINEC) Score System in Diagnosing Necrotizing Fasciitis: A Nested Case-Control Study. Infect Drug Resist. 2021; 14: 2105-12.

[12] Lin M, Li W, Yang Q, Xie Y, Feng W, Cai J, et al. Risk assessment of diabetic foot complicated with necrotizing fasciitis. Chin J Diabetes. 2020; 12: 312-7. China.

[13] Liu B, Hu J, Song Y, He W, Cheng Q, Wang Z, et al.; Chongqing Primary Aldosteronism Study (CONPASS) Group. Seated Saline Suppression Test Is Comparable With Captopril Challenge Test for the Diagnosis of Primary Aldosteronism: A Prospective Study. Endocr Pract. 2021; 27: 326-33.

[14] Yang Q, Ni X, Zhang Y, Zhu B, Zeng Q, Yang C, et al. Sarcopenia is an independent risk factor for all-cause mortality rate in patients with diabetic foot ulcers. Front Nutr. 2023; 10: 1097008.

[15] Lipsky BA, Senneville É, Abbas ZG, Aragón-Sánchez J, Diggle M, Embil JM, et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020; 36: e3280.

[16] Wagner FW Jr. The dysvascular foot: a system for diagnosis and treatment. Foot Ankle. 1981; 2: 64-122.

[17] Karimi K, Odhav A, Kollipara R, Fike J, Stanford C, Hall JC. Acute Cutaneous Necrosis: A Guide to Early Diagnosis and Treatment. J Cutan Med Surg. 2017; 21: 425-37.

[18] Ahn J, Raspovic KM, Liu GT, Lavery LA, Fontaine JL, Nakonezny PA, et al. Lower Extremity Necrotizing Fasciitis in Diabetic and Nondiabetic Patients: Mortality and Amputation. Int J Low Extrem Wounds. 2019; 18: 114-21.

[19] Yu H, Zhang M, Chen M. Research progress of necrotizing fasciitis. Trauma Crit Care Med. 2023; 11: 66-70. China.

[20] Sun Z. Investigation into risk factors of diabetic foot in type 2 diabetic patients. J Dermatology and Venereology. 2020; 42: 257-8. China.

[21] Chen PC, Tsai SH, Wang JC, Tzeng YS, Wang YC, Chu CM, et al. An elevated glycemic gap predicts adverse outcomes in diabetic patients with necrotizing fasciitis. PLoS One. 2019; 14: e0223126.

[22] Liu J, Huang Q, Liu F. Fat talks first: how adipose tissue sets the pace of aging? Life Med. 2025; 4: lnaf028.

[23] Herr M, Grabein B, Palm HG, Efinge K, Riesner HJ, Friemert B, et al. Nekrotisierende Fasziitis. Unfallchirurg. 2011; 114: 197-216.

[24] Schuster L, Nuñez DE. Using clinical pathways to aid in the diagnosis of necrotizing soft tissue infections synthesis of evidence. Worldviews Evid Based Nurs. 2012; 9: 88-99.

[25] Khamnuan P, Chongruksut W, Jearwattanakanok K, Patumanond J, Tantraworasin A. Necrotizing fasciitis: epidemiology and clinical predictors for amputation. Int J Gen Med. 2015; 8: 195-202.

[26] Zakariah NA, Bajuri MY, Hassan R, Ismail Z, Md Mansor M, Othman H, et al. Is Procalcitonin more superior to hs-CRP in the diagnosis of infection in diabetic foot ulcer? Malays J Pathol. 2020; 42: 77-84.

[27] Liew PX, Kubes P. The Neutrophil’s Role During Health and Disease. Physiol Rev. 2019; 99: 1223-48.

[28] Xue M, Zhang S, Xie J, Zhang X, Liu F, Huang Y, et al. Differential expression of genes associated with T lymphocytes function in septic patients with hypoxemia challenge. Ann Transl Med. 2019; 7: 810.

[29] Kim J, Yoo G, Lee T, Kim JH, Seo DM, Kim J. Classification Model for Diabetic Foot, Necrotizing Fasciitis, and Osteomyelitis. Biology (Basel). 2022; 11: 1310.

[30] Tang W. Clinical Study of the Impact of Hemoglobin Levels on Prognosis in Patients with Sepsis [dissertation]. Guangzhou: Guangzhou University of Traditional Chinese Medicine; 2021. China.